AstraZeneca PLC (Nasdaq: AZN) announced on November 13, 2026, that the United States Food and Drug Administration has approved IMFINZI (durvalumab) in combination with enfortumab vedotin-ejfv before surgery, followed by IMFINZI alone after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval establishes a new perioperative treatment option supported by the Phase 3 VOLGA trial, which demonstrated statistically significant improvements in event-free and overall survival compared with surgery-based care.
The decision converts AstraZeneca’s previously investigational regimen into an authorised treatment option and expands the company’s existing perioperative bladder cancer portfolio. In VOLGA, durvalumab combined with enfortumab vedotin reduced the hazard of an event or death by 49% and the hazard of death by 42% relative to the trial control group. However, the regimen also produced a higher incidence of severe adverse events, and its clinical positioning will be influenced by the availability of another approved perioperative combination involving enfortumab vedotin and pembrolizumab.
The approval follows FDA Priority Review and was granted approximately six weeks before the agency’s target decision date. It is based on evidence presented at the October 2026 European Society for Medical Oncology Congress and published in the New England Journal of Medicine. The regulatory milestone is distinct from the earlier clinical data disclosure because it establishes the precise patient population, treatment sequence and prescribing framework under which the combination can now be marketed in the United States.
What exactly did the FDA approve for cisplatin-ineligible muscle-invasive bladder cancer?
The new indication covers adults with muscle-invasive bladder cancer who are candidates for radical cystectomy but are ineligible for or have refused cisplatin-based chemotherapy. Treatment involves durvalumab and enfortumab vedotin-ejfv before surgery, followed by durvalumab alone after bladder removal. The approval does not establish the regimen for every patient with bladder cancer or authorise the same treatment sequence across all disease stages.
The distinction is clinically important because muscle-invasive bladder cancer can require complex treatment involving systemic therapy and major surgery. Cisplatin-based chemotherapy has historically played an important role before cystectomy, but some patients cannot receive it because of impaired kidney function or other clinical limitations. Others may decline cisplatin despite being considered eligible.
Before the availability of newer perioperative strategies, patients unable or unwilling to receive cisplatin often had fewer systemic treatment options before surgery. Radical cystectomy could provide definitive local treatment, but recurrence and distant disease remained substantial concerns. The new approval addresses this treatment setting using an antibody-drug conjugate combined with immune checkpoint inhibition.
The FDA-authorised regimen begins with three cycles of neoadjuvant treatment. Durvalumab is administered every three weeks in combination with enfortumab vedotin on Days 1 and 8 of each cycle, followed by radical cystectomy where clinically appropriate. After surgery, durvalumab is administered every four weeks for up to nine cycles.
The authorised treatment sequence requires coordination between medical oncology, urology and surgical teams. Patients must be assessed for their ability to receive systemic therapy before surgery and for continued postoperative treatment. The regimen’s practical success will depend on delivering those stages appropriately without compromising definitive local management.
The approval does not remove the need to evaluate individual clinical characteristics and treatment-related risks. It establishes an additional authorised option within a defined population rather than replacing every existing perioperative approach.
How did the VOLGA Phase 3 trial establish a survival benefit?
VOLGA was a randomised, open-label Phase 3 trial enrolling 695 patients with muscle-invasive bladder cancer who were candidates for radical cystectomy and were ineligible for or refused cisplatin-based chemotherapy. Participants were assigned across three treatment groups, including durvalumab with enfortumab vedotin, an additional experimental regimen containing tremelimumab, and a surgery-based control group. The principal analysis supporting the new approval compared the durvalumab and enfortumab vedotin regimen with the control strategy.
The relevant groups included 233 patients assigned to durvalumab with enfortumab vedotin and 229 assigned to control treatment. The primary efficacy endpoint was event-free survival assessed by blinded independent central review. Overall survival was an additional efficacy endpoint, allowing the investigators to assess whether delaying disease-related events was accompanied by longer survival.
The study demonstrated a statistically significant improvement in event-free survival, with a hazard ratio of 0.51 and a 95% confidence interval of 0.38 to 0.67. The associated p-value was below 0.0001, supporting the conclusion that the observed difference was unlikely to be explained by chance under the prespecified analysis framework. Median event-free survival had not been reached in the combination group, compared with 12.1 months in the control group.
At 24 months, estimated event-free survival was 63.5% with the durvalumab and enfortumab vedotin regimen, compared with 45.1% for control treatment. This represents an absolute difference of 18.4 percentage points at the two-year assessment. The relative hazard reduction and absolute difference describe different aspects of the treatment effect and should not be used interchangeably.
The event-free survival endpoint incorporated multiple clinically important events, including disease progression, recurrence and other events defined by the trial protocol. Therefore, the reported 49% lower hazard should not be described solely as a 49% reduction in the probability of cancer recurrence. It reflects the composite endpoint evaluated in the study.
The strongest evidence supporting the clinical significance of the findings comes from overall survival. VOLGA demonstrated a hazard ratio for death of 0.58, with a 95% confidence interval of 0.40 to 0.83 and a p-value of 0.0027. The result corresponds to a 42% lower hazard of death during the observed follow-up period.
At two years, estimated overall survival was 78.4% with the combination and 69.4% in the control group. The nine-percentage-point absolute difference provides a clinically interpretable measure alongside the relative hazard reduction. Median overall survival had not been reached in either group, meaning further follow-up will be valuable for understanding longer-term outcomes.
These results provide a stronger regulatory foundation than a trial demonstrating only an improvement in a surrogate or composite endpoint. The observed overall survival benefit supports the conclusion that the treatment strategy can improve an outcome directly relevant to patients. Nevertheless, the magnitude and durability of the benefit will continue to be evaluated as follow-up matures.
Why does the safety profile remain important despite the survival advantage?
The VOLGA trial demonstrated a meaningful survival benefit, but treatment-related toxicity and the broader adverse-event burden require consideration. Grade 3 or higher adverse events of any cause occurred in 71.1% of patients receiving durvalumab and enfortumab vedotin, compared with 50.2% in the control group. Treatment-related Grade 3 or higher events were reported in 30.7% of patients in the combination group.
The distinction between all-cause and treatment-related adverse events is important in a perioperative cancer study. Patients may experience complications associated with the underlying disease, surgery, comorbidities or systemic treatment. Attribution must therefore be considered alongside event severity when evaluating the regimen’s tolerability.
Reported adverse events in the combination group included rash, pruritus, urinary tract infections, fatigue, gastrointestinal symptoms and peripheral neuropathy. Laboratory abnormalities included changes involving liver enzymes, blood counts and kidney-related measurements. These findings are consistent with the need to monitor overlapping toxicities associated with an antibody-drug conjugate and immune checkpoint inhibition.
Durvalumab blocks programmed death-ligand 1, allowing immune activity against tumour cells but also creating the potential for immune-mediated adverse reactions. Enfortumab vedotin targets Nectin-4 and delivers a cytotoxic payload to targeted cells, with recognised risks including skin reactions and peripheral neuropathy. Combining the medicines requires consideration of toxicities associated with both components.
The FDA’s safety information identifies immune-mediated adverse reactions, infusion-related reactions and other established durvalumab warnings. The approved regimen must also be delivered in accordance with the relevant enfortumab vedotin prescribing requirements. The fact that a combination is authorised does not establish that it is suitable for every patient within the broad disease category.
The perioperative setting creates an additional consideration because treatment occurs before potentially curative surgery. Severe toxicity could affect a patient’s clinical condition or delay subsequent treatment. Oncology teams must therefore evaluate not only antitumour activity but also whether the treatment sequence can be completed appropriately.
VOLGA reported that radical cystectomy was performed in approximately 85% of patients assigned to the durvalumab and enfortumab vedotin regimen, compared with approximately 79% of control patients. These results suggest that the study treatment did not produce an overall reduction in the proportion proceeding to surgery. However, treatment completion and surgical complication data remain important for interpreting individual patient risks.
The survival benefit provides a strong rationale for the new approval, but the adverse-event profile will influence how clinicians balance the treatment’s potential advantages against its additional burden.
How does the new IMFINZI regimen differ from AstraZeneca’s existing NIAGARA-based approval?
AstraZeneca already holds a United States approval for perioperative durvalumab in muscle-invasive bladder cancer through the Phase 3 NIAGARA programme. That indication involves durvalumab combined with gemcitabine and cisplatin before surgery, followed by durvalumab alone after radical cystectomy. It applies to the appropriate cisplatin-eligible population.
NIAGARA demonstrated statistically significant improvements in event-free and overall survival, establishing a role for durvalumab within a perioperative chemotherapy-based treatment strategy. The new VOLGA approval expands the company’s offering into a setting where patients cannot or will not receive cisplatin. This creates two authorised approaches using the same immune checkpoint inhibitor but different preoperative treatment partners.
The mechanisms of the combinations differ. In NIAGARA, durvalumab is administered alongside conventional platinum-based chemotherapy, while the VOLGA regimen combines durvalumab with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. These differences influence treatment-related risks, administration requirements and the clinical populations studied.
The two approvals should not be interpreted as establishing that one durvalumab regimen is superior to the other. NIAGARA and VOLGA enrolled different patient populations and used different comparator strategies. Their efficacy estimates therefore cannot be reliably compared to determine the preferred treatment for an individual patient.
The additional indication nevertheless strengthens AstraZeneca’s perioperative bladder cancer position. It allows the company to offer an authorised durvalumab-based strategy across different cisplatin eligibility circumstances, subject to each label’s specific requirements. This creates opportunities for broader clinician engagement and treatment pathway development.
However, the expansion also adds operational complexity. Hospitals must distinguish between the approved regimens and ensure that treatment selection, dosing and monitoring correspond to the intended population. The existence of two durvalumab-based approaches does not remove the need for precise patient assessment.
Can AstraZeneca compete with the approved PADCEV and KEYTRUDA regimen?
The commercial environment has changed substantially since VOLGA began. Enfortumab vedotin, marketed as PADCEV, is already authorised in combination with pembrolizumab, marketed as KEYTRUDA, for perioperative treatment in muscle-invasive bladder cancer. This creates an important competitive setting for the newly approved durvalumab-based regimen.
The pembrolizumab and enfortumab vedotin combination was initially approved in November 2025 for patients who were ineligible for or declined cisplatin-based chemotherapy. Its United States indication was expanded in July 2026 following additional Phase 3 evidence, broadening its use among adults with muscle-invasive bladder cancer who are candidates for cystectomy. As a result, AstraZeneca is entering a treatment category where a competing antibody-drug conjugate and checkpoint inhibitor regimen is already established.
The two combinations share enfortumab vedotin but use different immune checkpoint inhibitors. Durvalumab targets PD-L1, while pembrolizumab targets PD-1. Both approaches seek to enhance antitumour immune activity, although differences in molecular targets, trial designs and treatment schedules can influence how the regimens are evaluated.
There is no direct randomised trial establishing that the newly approved durvalumab combination is superior or inferior to perioperative pembrolizumab with enfortumab vedotin. Differences between VOLGA and the studies supporting the pembrolizumab regimen prevent reliable comparisons based solely on hazard ratios. Clinicians should not infer relative superiority from numerical differences between separate trial programmes.
The competitive question will therefore extend beyond efficacy estimates. Safety management, clinical experience, treatment schedules, approved indications and institutional treatment pathways may influence prescribing decisions. Hospitals and payers may also consider drug acquisition costs and the resources required to deliver each regimen.
AstraZeneca benefits from an established oncology commercial infrastructure and existing experience with IMFINZI in bladder cancer. However, the new approval does not automatically establish a distinct patient population unavailable to the competing regimen. Its commercial opportunity will depend on whether clinicians identify practical reasons to select durvalumab within the overlapping treatment setting.
The presence of multiple effective perioperative strategies may increase treatment choice, but it also creates a more demanding evidence environment. Future comparative research and real-world outcomes could become important in clarifying how the options should be positioned.
What does the FDA’s Project Orbis review mean for international availability?
The FDA assessed the durvalumab and enfortumab vedotin application through Project Orbis, an initiative intended to facilitate coordinated regulatory reviews of oncology medicines across participating jurisdictions. The review involved cooperation with authorities including Health Canada, Australia’s Therapeutic Goods Administration, the United Kingdom’s Medicines and Healthcare products Regulatory Agency and regulators in several other countries.
The process can help participating authorities consider oncology evidence within a coordinated framework. However, Project Orbis does not produce one international marketing authorisation. Each regulator remains responsible for evaluating the application and making its own decision under the relevant national requirements.
The November 13 approval therefore establishes the regimen’s authorised status in the United States. It does not automatically mean that the same indication has been approved in Canada, Australia, the United Kingdom or other participating markets. AstraZeneca must complete the applicable regulatory processes in those jurisdictions.
International commercialisation will also depend on reimbursement and healthcare system requirements after any approval. A positive regulatory decision does not guarantee that the regimen will be immediately available across all hospitals or funded under every national health programme. Pricing and health technology assessments may influence the timing and scale of adoption.
Project Orbis can support regulatory coordination, but the commercial trajectory remains jurisdiction-specific. The United States approval is the confirmed milestone, while additional international decisions should be evaluated as they occur.
What will determine whether the new IMFINZI approval changes clinical practice?
The FDA decision establishes that the totality of the VOLGA evidence supports an acceptable benefit-risk profile for the newly authorised indication. The trial demonstrated significant improvements in event-free and overall survival, addressing a clinically important treatment setting for patients who cannot or will not receive cisplatin-based chemotherapy. These findings provide a credible foundation for clinical adoption.
The implementation challenge concerns delivering the complete treatment sequence while managing adverse effects and preserving appropriate surgical care. Medical oncologists, urologists and multidisciplinary teams will need to coordinate preoperative therapy, radical cystectomy and postoperative treatment. Treatment-related toxicity, patient fitness and the ability to complete the planned regimen will influence real-world outcomes.
The competitive environment introduces a second challenge. AstraZeneca must establish where the durvalumab combination fits alongside perioperative pembrolizumab and enfortumab vedotin, as well as other approved treatment approaches. Without direct comparative evidence, treatment selection will depend on the available trial data, clinical judgement and practical treatment considerations.
Longer-term VOLGA follow-up will also be relevant. Additional survival information could clarify the durability of the observed advantage, while continued safety assessment may provide a more complete picture of treatment burden. Real-world evidence may eventually help explain how the regimen performs in patients with greater comorbidity or different clinical characteristics than those enrolled in the trial.
The November 13 approval moves AstraZeneca’s VOLGA regimen beyond regulatory uncertainty and into clinical implementation. Its survival results justify the new treatment option, but the next phase will be defined by multidisciplinary delivery, safety management and competitive positioning. The decisive test is whether the approved regimen can reproduce its trial-supported benefits in routine bladder cancer care while offering a practical alternative within an increasingly crowded perioperative treatment landscape.
